Company Number: 15218793

Analysis Date: 2025-07-29 15:04 UTC

Financial Health Assessment for IK Clinical Development Limited

---

1. Financial Health Score: D

Explanation:
The company is a newly formed micro-entity with its first financial year ended October 2024. It currently shows net liabilities (negative net assets) and working capital deficit, indicating initial financial strain typical of a start-up stage. While not unusual for a new company, this score reflects the need for close monitoring and corrective actions to improve financial stability.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Current Assets	14,456	Cash and short-term receivables; relatively low but positive
Current Liabilities	15,652	Short-term debts and payables slightly exceed current assets
Net Current Assets (Working Capital)	-1,196	Negative working capital indicates liquidity strain
Net Assets (Shareholders' Funds)	-1,196	Negative equity suggests liabilities exceed assets
Number of Employees	1	Very small operation, typical for micro-sized start-up

• Liquidity: The company has a "symptom of distress" in liquidity as current liabilities marginally exceed current assets, risking short-term cash flow issues.
• Solvency: Negative net assets indicate the company is currently insolvent on a balance sheet basis, a common early-stage scenario but one that requires attention.
• Scale: As a micro-entity, the company has minimal operational complexity but limited financial buffer.
• Governance: The sole director holds full control, which simplifies decision-making but concentrates risk.

---

3. Diagnosis

IK Clinical Development Limited is in its infancy, having been incorporated in October 2023 and reporting its first set of accounts ending October 2024. The financial "vitals" show typical early-stage symptoms:

• Working Capital Deficit: The company owes slightly more in short-term liabilities than it holds in current assets, implying a potential cash crunch. This is akin to a patient with low blood pressure—manageable but requiring intervention.
• Negative Net Assets: The company’s liabilities exceed its assets by £1,196. While small in absolute terms, this is a red flag for solvency and long-term sustainability if not addressed.
• Limited Operational Scale: With only one employee and limited financial resources, the business is highly vulnerable to external shocks or operational delays.

However, these symptoms are common for start-ups in the clinical development sector, where upfront investment precedes revenue generation. The company’s exemption from audit and micro-entity reporting provisions reduce compliance burden, allowing focus on growth.

---

4. Recommendations

To improve financial wellness and move towards a healthier financial state, the company should consider:

• Strengthen Liquidity: Increase cash reserves or reduce short-term liabilities. This may involve negotiating longer payment terms with creditors or securing short-term financing.
• Capital Injection: Since the shareholder currently owns 75-100%, consider an additional capital injection to eliminate negative equity and provide a buffer for operational needs.
• Cash Flow Management: Implement rigorous cash flow forecasting and control to prevent liquidity crises. Monitor incoming contracts or funding timelines closely.
• Business Development: Accelerate commercial activities to generate revenue, reducing reliance on external capital.
• Governance Controls: Although the director is sole controller, consider preparing for growth by establishing financial oversight, even informal, to detect early warning signs.
• Regular Financial Review: Quarterly financial health checks focusing on liquidity and solvency metrics will help catch problems early.

---